AI assistant
Terns Pharmaceuticals, Inc. — Director's Dealing 2024
Aug 6, 2024
32559_dirs_2024-08-05_039f967a-756d-48cd-bc9d-0bdc9cdd876d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2024-08-01
Reporting Person: Quigley Jill M. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-08-01 | Common Stock | S | 6143.00 | $7.6751 | Disposed | 23857.00 | Direct |
| 2024-08-02 | Common Stock | S | 8857.00 | $7.5005 | Disposed | 15000.00 | Direct |
Footnotes
F1: Represents shares of common stock sold to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person. Such sales do not represent a discretionary trade by the Reporting Person.
F2: This sale price represents the weighted average sale price of the shares sold ranging from $7.505 to $7.815 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2024.
F4: This sale price represents the weighted average sale price of the shares sold ranging from $7.35 to $7.67 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.